Harrow Reports Q4 Revenue Beat, Issues Strong 2026 Guidance
Summary
Harrow, Inc. reported Q4 revenue of $89.10 million, slightly exceeding analyst estimates of $88.45 million, marking a 33% year-over-year increase. The ophthalmic solutions provider also issued its 2026 financial guidance, projecting revenue between $350 million and $365 million and adjusted EBITDA of $80 million to $100 million. This positive outlook, driven by strong demand for key products like VEVYE and IHEEZO and expanded sales teams, provides new material information for traders to assess the company's future growth trajectory and operational efficiency. Investors will now focus on the company's ability to execute on its ambitious 2026 targets.
At the time of this announcement, HROW was trading at $48.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $20.85 to $54.85. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.